NCT00520325撤回1 期
A Multi-Center Study of the Safety, Tolerability, Pharmacokinetics, and Dose Escalation of Intravenous Recombinant Human Mannose-Binding-Lectin (rhMBL) in MBL Deficient Pediatric Hematology/Oncology Patients With Fever and Neutropenia
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 主要终点
- Determine the safety and tolerability of intravenous rhMBL administered at dosages of 0.5 and 1.0 mg/kg to MBL deficient pediatric hematology/oncology patients during episodes of fever and neutropenia.
研究概览
简要总结
The goal of this clinical research study is to find the dose of EZN-2232 that can be given to MBL deficient pediatric cancer patients undergoing chemotherapy. The pharmacokinetics, pharmacodynamics, and safety of the study drug will also be studied.
详细描述
MBL deficient patients will be randomized in a ratio of 1:1 to receive a single dose of either 0.5 mg/kg or 1.0 mg/kg of intravenous rhMBL. A total of 24 patients will be treated in each of the rhMBL arms, (12 in the 0.5 mg/kg and 12 in the 1.0 mg/kg. All patients are to receive anti-infectious prophylactic supportive therapy as per institutional standards
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must meet all of the following criteria to be eligible for enrollment into the study:
- •Children ages 2 to 17 receiving chemotherapy for hematological/oncological diseases.
- •Patients must have documented MBL levels <300 ng/mL in serum as evaluated in the screening protocol.
- •Fever defined as an oral temperature equivalent of >100.4°F (38°C).
- •Neutropenia defined as an absolute neutrophil count ≤1,000/mm3 with the anticipation that the counts will fall below 500/mm
- •Receiving broad spectrum antibiotics for fever and neutropenia.
- •Patients with age-adjusted normal serum creatinine OR a creatinine clearance >60 mL/min/1.73m
- •Informed consent of the patient, parent or legally authorized representative obtained prior to entry.
- •Reliable and willing to make themselves available for the duration of the study and to abide by the study restrictions.
排除标准
- •Patients meeting any of the following exclusion criteria will not be eligible for enrollment.
- •Patients receiving the preparative regimen for a bone marrow or hematopoietic stem cell transplantation.
- •Concurrent serious illness in the opinion of the principal investigator that could potentially interfere with protocol compliance.
- •Patient is pregnant, breast feeding or planning a pregnancy during the course of the study.
- •Sexually active male and female patients not using an acceptable barrier method of contraception or practicing abstinence throughout the study and for at least 30 days after receiving their last treatment unless the patient is surgically or medically sterile.
- •Patients with moderate or severe liver disease, as defined by:
- •AST or ALT >5 times upper limit of normal (ULN) OR Total bilirubin >2.5 times ULN.
- •Patients with poor venous access that would preclude intravenous drug delivery or multiple blood draws.
- •Current participation in another clinical study with an investigational agent and/or use of an investigational drug (not including investigational use of an FDA approved drug) in the 30 days before scheduled administration of rhMBL.
- •Known allergic reactions to MBL or other human plasma products.
- •Patients on hemodialysis unable to tolerate the volume of IV fluid on non-dialysis days.
研究组 & 干预措施
0.5 mg/kg
Other
干预措施: Intravenous recombinant human mannose binding lectin (Drug)
1.0 mg/kg
Other
干预措施: Intravenous recombinant human mannose binding lectin (Drug)
结局指标
主要结局
Determine the safety and tolerability of intravenous rhMBL administered at dosages of 0.5 and 1.0 mg/kg to MBL deficient pediatric hematology/oncology patients during episodes of fever and neutropenia.
时间窗: 1 month
次要结局
- Determine the PK profile of intravenous rhMBL as a single dose escalation cohort design in MBL deficient pediatric oncology patients during episodes of fever and neutropenia.(1 month)
研究者
相似试验
已完成
1 期
A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02)Advanced Solid TumorsLymphomaNCT00520390Enzon Pharmaceuticals, Inc.34
已完成
1 期
A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01)Advanced Solid TumorsLymphomaNCT00520637Enzon Pharmaceuticals, Inc.34
进行中（未招募）
2 期
Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the ElderlyRespiratory Tract InfectionsNCT03373903Restorbio Inc.652
终止
2 期
A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With MethotrexateRheumatoid ArthritisNCT01679951Janssen Research & Development, LLC272
终止
1 期
Study of EZN-2208 Pediatric Patients With Solid TumorsSolid TumorsNCT01295697Enzon Pharmaceuticals, Inc.32